Full Press Release Details
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting.
ARGX
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
Key Takeaway: argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis